Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fibrinolytic Therapy vs VATS for Parapneumonic Effusion
NCT03583931Completed
- Sponsor
- Denver Health
- Start
- Jul 2018
- Primary completion
- Feb 2020
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of tissue-plasminogen activator and dornase alfa in parapneumonic effusion and empyema (2 arms), sponsored by Denver Health. Primary endpoint: Hospital Length of Stay. Started Jul 2018; status: completed.
02
Drugs
tissue-plasminogen activatordornase alfa
03
Conditions
parapneumonic effusionempyema
Beyond the preview
Go deeper on NCT03583931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583931.